Journal article icon

Journal article

PemBla: a Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer

Abstract:

Objectives: This study aimed to investigate the anti-PD-1 inhibitor pembrolizumab as a potential agent for use in non-muscle-invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run-in study to assess the safety and tolerability of intravesical pembrolizumab after transurethral resection of the bladder tumour (TURBT).

Patients and methods: Eligible patients had recurrent NMIBC for which adjuvant treatment post TURBT was a reasonable treat...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/bco2.220

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Research group:
MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine
Role:
Author
ORCID:
0000-0001-7656-728X
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
Weatherall Insti. of Molecular Medicine
Research group:
MRC Human Immunology Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Research group:
Oncology Clinical Trials Office
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Research group:
Oncology Clinical Trials Office
Role:
Author
Publisher:
Wiley
Journal:
BJUI Compass More from this journal
Volume:
4
Issue:
3
Pages:
322-330
Publication date:
2023-01-13
Acceptance date:
2022-12-30
DOI:
EISSN:
2688-4526
Language:
English
Keywords:
Pubs id:
1324980
Local pid:
pubs:1324980
Deposit date:
2023-01-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP